申请人:Merck Sharp & Dohme Corp.
公开号:US20140309213A1
公开(公告)日:2014-10-16
This invention relates to compounds of Formula I-VI having the following general structure:
Z
1
—Y
1
—(CH
2
)
n1
—R—(CH
2
)
n2
—Y
2
—Z
2
wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with —(CH
2
)
n1
— and —(CH
2
)
n2
—, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
本发明涉及具有以下一般结构的I-VI式化合物:Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2,其中R是一个6-8成员饱和杂环环,具有2个氮原子与分别连接的—(CH2)n1—和—(CH2)n2—,以及其药学上可接受的盐,它们是肾外髓钾(ROMK)通道(Kir1.1)的抑制剂。该化合物可用作利尿剂和钠利尿剂,因此可用于治疗和预防由过度盐和水潴留引起的疾病,包括高血压和慢性和急性心力衰竭等心血管疾病。